All case studies

Highlights

We focus our innovation on the factors that matter most — accelerating time to market, reducing costs and enhancing quality. Learn more about how we've helped clients meet and exceed their goals in this selected library of case studies.

Proactive patient retention strategy in a GLP-1 RA trial

Explore how ICON successfully supported a sponsor’s cardiovascular outcome trial for a GLP-1 receptor agonist with 9,900+ patients with type 2 diabetes and maintained a retention rate of 97% over 7 years.

A small biotech success story

A small US-based biotech company was in a race to be the first to market with their lead targeted oncology product.

FSP partnership - sustained efficiency and ongoing innovation

The implementation of an FSP model across our partner's project management function, led to 20% cost efficiences and a 30% reduction in client burden.

By taking a site and patient-centric approach, and leveraging advanced tools and real-time data insights, we maximise patient access, recruitment, and retention—ensuring that every trial is conducted with efficiency, agility, and a commitment to improving patient outcomes.

All case studies

Filter our case studies by categories, selecting amongst our broad range of solutions.

Combined study with in vitro device investigating an oncology treatment

A study sponsor was investigating a biological treatment for oncology patients in addition to the standard of care chemotherapy. They sought regulatory support from ICON due to the study’s complexity, the geographic span and because the IVD was used out of its intended purpose.

Proactive patient retention strategy in a GLP-1 RA trial

IRT User Acceptance Testing

Resolving critical issues and ensuring trial integrity

Regulatory Strategy in Clinical Development (EU)

"A large pharma customer sought expert regulatory support from ICON for a paediatric rare disease development
program."

Increased compliance for complex Alzheimer’s disease study

The sponsor in this case was a large pharmaceutical company that contracted ICON to manage and streamline the training and compliance workload for their phase 2 Alzheimer’s study.

Multinational phase 1 biosimilar study

ICON conducted a multinational biosimilar phase 1 study for multiple sclerosis (MS). This trial was performed under high regulatory scrutiny and challenging pandemic conditions, with increased dosing targets requiring additional site activation.

Exceeding recruitment timelines in a double-blind multiple system atrophy (MSA) study

ICON conducted a multi-centre study to assess the efficacy, safety, and tolerability of an anti-α-synuclein human immunoglobulin G1 monoclonal antibody in patients with Multiple System Atrophy followed by an open label extension.

IVDR Technical File Remediation

ICON was tasked with developing a remediation program encompassing a product portfolio spanning more than seven automated instruments and more than 500 analytes or assays.

Voice & speech recognition

ICON Outcome Measures found well-validated tools for processing data associated with speech cadence, vocal pitch, and similar measures to evaluate rates of change in neurologic and psychiatric disorders.

Evolving quality oversight to limit sponsor burden

ICON implemented a Data Management Asset Lead (DMAL) role to provide oversight and ensure adherence to standards for a sponsor with limited bandwidth.

Patient cardiac safety

A digital health lead at a large pharmaceutical company came to ICON Outcome Measures to find a wearable that could capture continuous cardiac rhythms and be used to detect QT prolongation.

Applying statistical and programming expertise to overcome FDA challenges

ICON supported a biotech company in preparing for FDA submission by quickly mobilising a team to address unexpected comments on statistical analysis and data collection, resulting in timely BLA submission, enhanced data quality, and alignment with FDA requirements.

Solutions case studies

Our solutions span the entire lifecycle of product development and can be adapted to suit small local trials or large global programs. Explore our work in the different aspects of our solutions.

Let's collaborate

Discover how ICON's expertise transforms clinical trials.

Blogs

Stay informed with ICON's expert insights on clinical trials, regulatory changes, and industry trends. Our blogs provide practical advice, innovative solutions, and thought leadership from global experts.

News

Stay updated with our latest news on partnerships, financial results, technological advancements, and industry insights.

Insights

Explore ICON's expert analysis and practical advice on the latest operational, regulatory, technological and economic challenges in clinical research. Our insights provide thought leadership and innovative solutions to transform trials.

Case studies

Highlights

Proactive patient retention strategy in a GLP-1 RA trial

A small biotech success story

FSP partnership - sustained efficiency and ongoing innovation

All case studies

Combined study with in vitro device investigating an oncology treatment

Proactive patient retention strategy in a GLP-1 RA trial

IRT User Acceptance Testing

Regulatory Strategy in Clinical Development (EU)

Increased compliance for complex Alzheimer’s disease study

Multinational phase 1 biosimilar study

Exceeding recruitment timelines in a double-blind multiple system atrophy (MSA) study

IVDR Technical File Remediation

Voice & speech recognition

Evolving quality oversight to limit sponsor burden

Patient cardiac safety

Applying statistical and programming expertise to overcome FDA challenges

Solutions case studies

Let's collaborate

Blogs

News

Insights